Phospho-PRKCD (Tyr64) Antibody

What is the significance of tyrosine phosphorylation in PRKCD compared to other PKC family members?

Unlike other PKC family members, PKCδ activation is uniquely regulated by tyrosine phosphorylation patterns. Human PKCδ contains 20 tyrosine residues (19 in mice and 21 in rat), including phosphorylation sites in the regulatory domain (Tyr-52, Tyr-64, Tyr-155, and Tyr-187), the hinge region (Tyr-311 and Tyr-332), and the catalytic domain (Tyr-505, Tyr-512, and Tyr-523) . While serine and threonine phosphorylation is conserved among different PKCs, tyrosine phosphorylation is distinctive to PKCδ regulation . This unique regulatory mechanism makes phospho-specific antibodies particularly valuable for studying PKCδ activation in various cellular contexts.

Tyrosine phosphorylation in the regulatory domain (including Tyr-64) influences cellular actions rather than catalytic competence, while phosphorylation in the catalytic domain generally increases PKCδ enzymatic activity . This compartmentalized regulation through distinct phosphorylation patterns allows for fine-tuned control of PKCδ function in response to different cellular stimuli.

How does phosphorylation at Tyr64 specifically contribute to PRKCD function?

Phosphorylation at Tyr64 plays a crucial role in activating PKCδ in response to apoptotic stimuli by facilitating its nuclear import . Research has identified c-Src as the specific kinase responsible for phosphorylating PKCδ at Tyr64 . This phosphorylation event represents a key activation mechanism during apoptotic signaling cascades.

Functionally, Tyr64 phosphorylation enables PKCδ to bind to importin-α, facilitating its translocation to the nucleus where it can regulate apoptotic gene expression . This nuclear translocation is essential for PKCδ's pro-apoptotic functions, as demonstrated by experiments with tyrosine kinase inhibitors that block this phosphorylation and subsequently inhibit nuclear accumulation of PKCδ . The physiological significance of this pathway is underscored by studies showing that blocking Tyr64 phosphorylation can suppress radiation-induced apoptosis in tissues like salivary glands, suggesting potential therapeutic applications .

What is the relationship between Tyr64 phosphorylation and other regulatory phosphorylation sites on PRKCD?

PKCδ regulation involves a complex interplay between multiple phosphorylation sites. In addition to Tyr64, PKCδ contains several other tyrosine phosphorylation sites as well as serine/threonine phosphorylation sites that collectively regulate its activity and function. A comprehensive study identified five novel Ser/Thr phosphorylation sites: Thr50, Thr141, Ser304, Thr451, and Ser506 following PKCδ overexpression in HCT116 human colon carcinoma cells .

The functional relationship between these sites reveals specialized roles:

While Tyr64 phosphorylation facilitates nuclear import, research indicates that Tyr155 and Tyr311 phosphorylation are also required for complete nuclear translocation and enzyme cleavage . These sites don't function in isolation but rather create a phosphorylation signature that determines PKCδ's ultimate cellular function and localization.

What are the optimal protocols for using Phospho-PRKCD (Tyr64) antibody in Western blotting?

Based on comprehensive analysis of manufacturer recommendations and research protocols, the following conditions represent optimized parameters for Western blotting with Phospho-PRKCD (Tyr64) antibody:

For optimal results, researchers should include a denaturing lysis buffer containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, and β-glycerophosphate) and protease inhibitors. Following transfer to PVDF or nitrocellulose membrane, blocking in 5% BSA rather than milk is recommended as milk contains phospho-proteins that may interfere with detection of phospho-epitopes.

How can researchers validate the specificity of Phospho-PRKCD (Tyr64) antibody in experimental systems?

Validating antibody specificity is essential for reliable research outcomes. For Phospho-PRKCD (Tyr64) antibody, a multi-faceted validation approach is recommended:

• Positive controls: Employ cell lysates from systems known to exhibit Tyr64 phosphorylation, such as cells treated with apoptotic stimuli including radiation or etoposide treatment .

• Negative controls: Include:

  • Dephosphorylated samples (treated with lambda phosphatase)

  • Samples treated with tyrosine kinase inhibitors like dasatinib that block Tyr64 phosphorylation

  • Lysates from cells with c-Src knockdown (the kinase responsible for Tyr64 phosphorylation)

• Peptide competition assay: Pre-incubate the antibody with the immunizing phosphopeptide. Many manufacturers use a synthetic peptide derived from human PKCD around the phosphorylation site of Tyr64 (amino acids 30-79) .

• Genetic validation: Utilize PRKCD knockout cells or cells expressing Y64F mutant PKCδ (tyrosine to phenylalanine substitution preventing phosphorylation).

• Cross-method validation: Compare results across multiple detection methods (Western blot, immunohistochemistry, ELISA) to ensure consistent detection .

The antibody detects endogenous levels of PKCδ only when phosphorylated at Tyr64, with no reported cross-reactivity to other proteins , but this specificity should be confirmed in each experimental system.

What controls are essential when designing experiments with Phospho-PRKCD (Tyr64) antibody?

A robust experimental design for studies using Phospho-PRKCD (Tyr64) antibody should include the following controls:

• Total PRKCD detection: Always probe for total PKCδ protein using a phosphorylation-independent antibody to normalize phospho-signal to total protein expression levels.

• Loading controls: Include standard loading controls such as β-actin, GAPDH, or α-tubulin to ensure equal protein loading across samples.

• Positive treatment control: Include samples treated with agents known to induce Tyr64 phosphorylation, such as:

  • Radiation exposure

  • Etoposide treatment

  • Phorbol esters (though these affect multiple PKC pathways)

• Negative controls:

  • Dasatinib treatment (blocks c-Src-mediated phosphorylation)

  • c-Src inhibition or knockdown

  • Y64F mutant PKCδ expression

• Isotype control: For immunohistochemistry applications, include appropriate isotype control (e.g., Rabbit IgG for rabbit polyclonal antibodies) .

• Subcellular fractionation: When studying PKCδ translocation, include nuclear and cytoplasmic fractions separately to track movement between compartments.

These controls not only validate antibody specificity but also provide crucial context for interpreting experimental results in relation to PKCδ signaling pathways.

How can Phospho-PRKCD (Tyr64) antibody be used to investigate nuclear translocation mechanisms?

Phosphorylation at Tyr64 is critical for PKCδ nuclear translocation and subsequent pro-apoptotic functions . Researchers can utilize Phospho-PRKCD (Tyr64) antibody to investigate this mechanism through several advanced approaches:

• Subcellular fractionation coupled with Western blotting: By separating nuclear and cytoplasmic fractions and probing with Phospho-PRKCD (Tyr64) antibody, researchers can quantify the nuclear accumulation of phosphorylated PKCδ following various stimuli.

• Immunofluorescence co-localization studies: Using Phospho-PRKCD (Tyr64) antibody in conjunction with nuclear markers (DAPI, lamin) allows visualization of PKCδ translocation in real-time or fixed cells.

• Importin-α binding assays: Co-immunoprecipitation studies using Phospho-PRKCD (Tyr64) antibody can identify interactions with nuclear import machinery. Research has shown that "Dasatinib and imatinib both blocked binding of PKCδ to importin-α and nuclear import, demonstrating that tyrosine kinase inhibitors can inhibit nuclear accumulation of PKCδ" .

• Time-course analysis: Monitoring Tyr64 phosphorylation kinetics following apoptotic stimuli can establish temporal relationships between phosphorylation, nuclear translocation, and apoptotic events.

• Mutation analysis: Comparing translocation of wild-type PKCδ versus Y64F mutant provides direct evidence of this phosphorylation site's role in nuclear targeting.

Such approaches have revealed that multiple phosphorylation events, including those at Tyr155 and Tyr311, work in concert with Tyr64 phosphorylation to regulate complete PKCδ nuclear translocation .

What approaches can be used to study the relationship between Tyr64 phosphorylation and apoptotic signaling pathways?

Apoptotic signaling represents one of the principal cellular processes regulated by PKCδ Tyr64 phosphorylation. Researchers can employ several sophisticated approaches to investigate this relationship:

• Apoptotic stimulus-response curves: Treat cells with increasing doses of apoptotic stimuli (radiation, etoposide) and quantify both Tyr64 phosphorylation and apoptotic markers (cleaved caspases, PARP cleavage, Annexin V) to establish dose-dependent correlations.

• Kinase inhibitor studies: As demonstrated in research, "Pretreatment with dasatinib, a broad spectrum tyrosine kinase inhibitor, blocked phosphorylation of PKCδ at both Tyr-64 and Tyr-155... Dasatinib and imatinib both blocked binding of PKCδ to importin-α and nuclear import... In vivo, pre-treatment of mice with dasatinib blocked radiation-induced apoptosis in the salivary gland by >60%" .

• Site-directed mutagenesis: Create phospho-mimetic (Y64E/Y64D) and phospho-deficient (Y64F) mutants to assess the specific contribution of this phosphorylation site to apoptotic signaling.

• Proteomic analysis: Employ phospho-PRKCD (Tyr64) antibody for immunoprecipitation followed by mass spectrometry to identify downstream effectors and binding partners specific to the Tyr64-phosphorylated form.

• In vivo models: Translating findings to animal models provides physiological context, as demonstrated by research showing dasatinib pre-treatment protected salivary glands from radiation-induced apoptosis .

These approaches collectively establish causal links between Tyr64 phosphorylation and apoptotic outcomes, informing potential therapeutic strategies for radiation protection or cancer treatment.

How does the phosphorylation status of Tyr64 influence PRKCD interactions with other signaling proteins?

Tyr64 phosphorylation creates docking sites for proteins containing SH2 domains, facilitating specific protein-protein interactions that direct PKCδ signaling outcomes. Several approaches can elucidate these interaction networks:

• Co-immunoprecipitation with Phospho-PRKCD (Tyr64) antibody: This approach identifies proteins that specifically interact with the Tyr64-phosphorylated form of PKCδ but not the unphosphorylated form.

• Proximity labeling techniques: BioID or APEX2 fused to PKCδ (wild-type or Y64F mutant) can identify the differential interactome based on Tyr64 phosphorylation status.

• Functional protein microarrays: Probing arrays with recombinant phosphorylated versus non-phosphorylated PKCδ can identify differential binding partners.

• SH2 domain array screening: Using phosphorylated peptides containing the Tyr64 region to screen SH2 domain arrays identifies potential interaction partners.

• Computational modeling: Structural modeling of the regulatory domain with Tyr64 phosphorylation can predict potential interaction interfaces and conformational changes.

Research has demonstrated that Tyr64 phosphorylation particularly affects PKCδ's interaction with nuclear import machinery, specifically importin-α . These molecular interactions ultimately determine PKCδ's subcellular localization and downstream signaling outcomes in response to various cellular stimuli.

What are common sources of non-specific signals when using Phospho-PRKCD (Tyr64) antibody, and how can they be mitigated?

Non-specific signals represent a common challenge when working with phospho-specific antibodies. For Phospho-PRKCD (Tyr64) antibody, researchers should be aware of these potential issues and corresponding solutions:

An effective validation approach is to use multiple antibodies targeting different epitopes of phosphorylated PKCδ. Based on the search results, several manufacturers offer Phospho-PRKCD (Tyr64) antibodies raised against similar immunogens, providing an opportunity for cross-validation .

How can researchers enhance detection sensitivity when working with low abundance Phospho-PRKCD (Tyr64)?

Detecting low-abundance phosphoproteins presents technical challenges that can be addressed through several optimization strategies:

• Phosphoprotein enrichment:

  • Utilize commercially available phosphoprotein enrichment kits

  • Employ immunoprecipitation with total PKCδ antibody followed by Western blotting with phospho-specific antibody

  • Use metal oxide affinity chromatography (MOAC) techniques for phosphopeptide enrichment prior to analysis

• Signal amplification methods:

  • Switch to highly sensitive ECL substrates (femtogram detection range)

  • Employ biotin-streptavidin amplification systems

  • Consider tyramide signal amplification for immunohistochemistry applications

• Increase starting material:

  • Scale up protein extraction

  • Concentrate samples using centrifugal filter devices

  • Pool samples from replicate experiments when appropriate

• Optimize transfer conditions:

  • Use PVDF membranes (higher protein binding capacity than nitrocellulose)

  • Employ wet transfer for high molecular weight proteins

  • Consider partial transfer times to prevent protein transfer-through

• Stimulate phosphorylation:

  • Treat cells with phosphatase inhibitors like okadaic acid

  • Use appropriate stimuli known to induce Tyr64 phosphorylation (radiation, etoposide)

• Enhance antibody-epitope interaction:

  • Optimize primary antibody incubation temperature and time

  • Consider membrane fixation with glutaraldehyde to prevent protein loss

  • Test different antibody dilution buffers (TBST with 1-5% BSA)

These approaches can significantly improve detection of low-abundance Phospho-PRKCD (Tyr64), enabling analysis of subtle regulatory changes in physiologically relevant conditions.

What are the most effective strategies for quantitative analysis of Phospho-PRKCD (Tyr64) levels across experimental conditions?

Accurate quantification of phosphorylation levels is essential for meaningful comparisons across experimental conditions. For Phospho-PRKCD (Tyr64), consider these quantitative approaches:

• Normalization strategies:

  • Always normalize phospho-signal to total PKCδ levels, not just loading controls

  • Calculate phospho/total ratios to account for expression differences

  • Consider dual-color detection systems that allow simultaneous detection of phospho and total protein

• Quantitative Western blotting:

  • Use fluorescent secondary antibodies rather than HRP for wider linear dynamic range

  • Include a standard curve of recombinant phosphorylated protein if available

  • Employ software like ImageJ with appropriate background subtraction

• Alternative quantitative methods:

  • ELISA: Commercial kits for PKCδ (Phospho-Tyr64) offer quantitative assessment

  • Phospho-flow cytometry: For single-cell resolution of phosphorylation status

  • Selected reaction monitoring (SRM) mass spectrometry: For absolute quantification

• Experimental design considerations:

  • Include biological replicates (minimum n=3)

  • Analyze technical replicates to assess method variability

  • Include time-course measurements to capture phosphorylation dynamics

• Statistical analysis:

  • Apply appropriate statistical tests based on data distribution

  • Consider ANOVA for multi-group comparisons

  • Account for multiple comparisons when analyzing several phosphorylation sites

By combining these approaches, researchers can achieve robust quantitative assessment of PKCδ Tyr64 phosphorylation changes across diverse experimental conditions, enabling more precise mechanistic insights into PKCδ regulation.

How can multiplexed detection of multiple PKCδ phosphorylation sites enhance understanding of its regulatory mechanisms?

The complex phosphorylation pattern of PKCδ, with multiple tyrosine and serine/threonine sites, necessitates simultaneous analysis of multiple sites to fully understand its regulation. Emerging multiplexed approaches include:

• Multiplex Western blotting: Using different fluorophore-conjugated secondary antibodies to detect multiple phosphorylation sites simultaneously on the same membrane after stripping and reprobing.

• Mass spectrometry-based phosphoproteomics: Enables unbiased detection of multiple phosphorylation sites and their stoichiometry. Research has identified "five novel Ser/Thr phosphorylation sites: Thr 50, Thr 141, Ser 304, Thr 451, and Ser 506 (human PKCδ numbering)" , demonstrating the power of this approach.

• Phospho-specific protein microarrays: Allow simultaneous detection of multiple phosphorylation events across numerous samples.

• Phospho-specific flow cytometry: Provides single-cell resolution of multiple phosphorylation sites to reveal cell-to-cell heterogeneity.

• Proximity ligation assays: Can detect specific combinations of phosphorylation sites that co-occur on the same PKCδ molecule.

These approaches will help elucidate the "phosphorylation code" of PKCδ, revealing how different combinations of phosphorylation events lead to distinct functional outcomes. For instance, understanding the interplay between Tyr64 phosphorylation (mediated by c-Src) and Tyr155 phosphorylation (mediated by c-Abl) could reveal synergistic or antagonistic effects on PKCδ function.

What therapeutic applications might emerge from understanding PRKCD Tyr64 phosphorylation mechanisms?

Research into PKCδ Tyr64 phosphorylation has revealed promising therapeutic applications, particularly in radioprotection and inflammatory conditions:

• Radioprotection of normal tissues: Research has demonstrated that "In vivo, pre-treatment of mice with dasatinib blocked radiation-induced apoptosis in the salivary gland by >60%. These data suggest that tyrosine kinase inhibitors may be useful prophylactically for protection of nontumor tissues in patients undergoing radiotherapy of the head and neck" . This provides a foundation for developing strategies to prevent radiation-induced damage to normal tissues.

• Inflammation regulation: PKCδ is "a critical regulator of the inflammatory response in cancer, diabetes, ischemic heart disease, and neurodegenerative diseases" . Targeting Tyr64 phosphorylation could provide a specific approach to modulate inflammatory responses in these conditions.

• Cancer treatment adjuvants: Understanding the dual role of PKCδ in promoting both cell survival and apoptosis, depending on context and phosphorylation status, could lead to combination therapies that specifically sensitize cancer cells to apoptosis.

• Biomarker development: Phospho-PRKCD (Tyr64) could serve as a biomarker for predicting treatment response or disease progression in conditions where PKCδ signaling plays a critical role.

• Drug discovery targets: The specific kinases (c-Src) and phosphatases regulating Tyr64 phosphorylation represent potential therapeutic targets for modulating PKCδ function with greater specificity than targeting PKCδ directly.

These applications highlight the translational potential of basic research into PKCδ phosphorylation mechanisms, particularly for radiation oncology and inflammatory disease management.

How might new technologies enhance detection and functional analysis of PRKCD Tyr64 phosphorylation in complex biological systems?

Emerging technologies are poised to revolutionize our understanding of PKCδ Tyr64 phosphorylation in physiologically relevant contexts:

• Genetically encoded biosensors: FRET-based sensors designed to detect PKCδ Tyr64 phosphorylation could enable real-time visualization of this event in living cells, providing unprecedented temporal and spatial resolution.

• CRISPR-Cas9 genome editing: Creating endogenous tagged PKCδ or phospho-site mutants (Y64F) at the genomic level ensures physiological expression levels and regulatory control while enabling visualization or functional analysis.

• Single-cell phosphoproteomics: Emerging technologies allowing phosphoprotein analysis at the single-cell level will reveal cell-to-cell variability in PKCδ phosphorylation within heterogeneous tissues.

• Tissue-clearing techniques: Combined with phospho-specific antibodies, these methods enable 3D visualization of PKCδ Tyr64 phosphorylation patterns within intact tissues or organoids.

• Spatial transcriptomics and proteomics: Correlating PKCδ Tyr64 phosphorylation with gene expression patterns in specific tissue regions will reveal the spatial context of PKCδ signaling.

• Microfluidic organ-on-a-chip models: These systems provide more physiologically relevant contexts for studying PKCδ phosphorylation dynamics compared to traditional cell culture.

• Computational modeling: Integration of phosphoproteomic data with structural biology and systems biology approaches can predict emergent properties of PKCδ signaling networks and generate testable hypotheses about regulatory mechanisms.

These technological advances will facilitate translation of findings from reductionist experimental systems to complex physiological and pathological contexts, ultimately enhancing the clinical relevance of PKCδ phosphorylation research.